Limited use of FIB‐4 index in patients under 65 years of age with type 2 diabetes mellitus

초록

<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>Screening for liver fibrosis holds significant importance in patients with type 2 diabetes mellitus (T2DM) due to their elevated risk of advanced hepatic fibrosis. However, it is recognized that the diagnostic performance of the Fibrosis‐4 (FIB‐4) index is relatively low in T2DM patients. Our study aims to explore the potential and limitations of utilizing FIB‐4 as a screening tool in patients with T2DM.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A retrospective biopsy cohort of 1906 patients with biopsy‐proven metabolic dysfunction‐associated steatotic liver disease from South Korea, Japan, and Taiwan. Diagnostic performance according to T2DM was again compared after propensity score matching on age, sex, and body mass index.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Patients with T2DM were significantly older than those without. The area under the receiver operating characteristic curve (AUROC) of FIB‐4 for ruling out advanced fibrosis in non‐T2DM patients was significantly higher than that of T2DM (0.821 vs. 0.761, <jats:italic>p</jats:italic> = 0.044). However, the AUROCs of FIB‐4 according to the same age groups showed no significant difference between patients with T2DM and without (all <jats:italic>p</jats:italic> > 0.05). In the middle‐aged group, the sensitivity of FIB‐4 for ruling out advanced hepatic fibrosis was 77.1% for T2DM and did not differ with that of non‐T2DM patients (73.0%) (<jats:italic>p</jats:italic> = 0.093). After propensity score matching of age, there was no statistically significant difference in the AUROCs of the T2DM and non‐T2DM groups (0.860 vs. 0.761, <jats:italic>p</jats:italic> = 0.142).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Although the diagnostic performance of FIB‐4 was found to be suboptimal in patients with T2DM, its limited use in individuals under 65 years of age with T2DM still holds value as a screening tool.</jats:p></jats:sec>

키워드